Note: Descriptions are shown in the official language in which they were submitted.
CA 02792137 2012-09-05
WO 2011/117334 1 PCT/EP2011/054512
REVERSE MICELLE SYSTEM COMPRISING
NUCLEIC ACIDS AND USE THEREOF
FIELD OF THE INVENTION
The present invention relates to reverse micelle system based on sterols,
acylglycerols, phospholipids
or sphingolipids and nucleic acids. The reverse micelle system of the
invention is able to cross mucosa
and cellular membranes. It thus allows vectorization of nucleic acids to
target sites. It is
advantageously useful in the pharmaceutical and dietetic fields.
BACKGROUND OF THE INVENTION
RNAi (RNA interference) and antisense (AS) strategies consist in silencing the
expression of a target
gene by the use of nucleic acids which allow the degradation or the
translational arrest of mRNA
target. New antisense applications (exon skipping, alternative splicing
correction), by masking the
mutation responsible for an alternative splicing default, have permitted the
synthesis of a functional
protein. Aptamers are nucleic acids capable of interacting with a target
protein and down regulating its
synthesis. The discovery of all these nucleic acids, and more recently siRNA ,
miRNA and RNAa has
opened wide perspectives in therapeutics for the treatment of diseases like
genetic diseases, cancers,
neurodegenerative diseases, infectious and inflammatory diseases or to block
cell proliferation and
diseases caused thereby.
However, these molecules are unstable in biological fluids, in van, and in
vivo, they display a poor
intracellular penetration and low bioavailability. These critical drawbacks
have limited their use in
therapeutics. As a result, clinical applications of said nucleic acids have
required chemical
modifications with the aim of retaining their capacity to knockdown protein
expression while
increasing stability and cellular penetration. Research groups have also
applied the nanotechnology
approach to improve their delivery, to overcome most barriers that hampered
the development of
nucleic acids delivery based therapies. To improve bioavailability, many
researchers have also
attempted to use alternative administration routes: ocular, skin, oral,
intramuscular. Those attempts
have not been totally satisfactory so far. For instance, some of these
attempts, more specifically assays
with nucleic acids in liposome carriers have stimulated immune response.
The inventors have previously uncovered that complexes could be obtained from
two organic
compounds isolated from plant extracts and respectively constituted of
sitosterol and acylglycerols and
hydrosoluble therapeutic agents (W02006/048772), these complexes being
particularly effective
agents as trans mucosal vectors of said therapeutic agents. Such vectorization
of hydrosoluble
CA 02792137 2012-09-05
W02011/117334 2 PCT/EP2011/054512
therapeutic agents affords an important decrease of the administered amounts
compared to their
administration in the absence of micelles as previously described.
Said complexes have been shown effective to vectorize hydrosoluble therapeutic
agents by mucosal
immediate administration. The stability of microemulsions containing
therapeutic agents is not
however always satisfactory to allow their development as delivery systems for
drugs and/or dietetic
compounds for example. Such development requires formulations to be stable
over longer periods of
time, for instance over several weeks or months at room temperature.
It is an object of the present invention to overcome disadvantages of the
prior art. There is an obvious
need for a safe and efficient nucleic acids therapeutic strategy, and in
particular for new tools that are
able to achieve efficient gene expression modulation based therapy. More
particularly, it is an object
of the invention to provide a drug delivery system comprising a nucleic acid,
in particular an
oligonucleotide, which can be for instance administered mucosally, giving rise
to a satisfactory drug
bioavailability in an active form.
Incorporation of a phospholipid or a sphingolipid, in particular in specific
amounts, in the foimulation
of microemulsions comprising high doses of nucleic acid surprisingly triggered
an important increase
in their stability.
The present invention describes new microemulsions formulations able to
vectorize high quantities of
nucleic acids, process of preparation and use thereof as delivery systems for
drugs and/or dietetic
compounds. "High" amounts refer here to amounts sufficient to obtain a
therapeutic activity at the
human scale, but that remain far lower than the amounts of nucleic acid
delivered in absence of
complexes.
This formulation advantageously renders possible the control and optimisation
of the composition
comprising micelles for their use in the pharmaceutical and dietetic fields.
SUMMARY OF THE INVENTION
The present invention relates to a delivery system for the release of a
nucleic acid, preferably
mucosally applied, as well as the compositions and methods for preparing the
delivery system. Herein
described are reverse micelle systems designed to reach this goal in a safe
and controlled manner. The
reverse micelle systems are able to be absorbed through mucosa and to
vectorize nucleic acids under a
protected form to any tissue of the organism.
More particularly, the present invention provides a reverse micelle transport
system for dispensing a
nucleic acid, in particular an oligonucleotide, capable of interaction with
pre-mRNA, mRNA or
3
protein, and modulation of gene expression. More specifically, reverse
micelles
according to the invention promote the absorption of the nucleic acid across
mucosal epithelial barriers and allow the nucleic acid to be internalised into
the
target- cells. The reverse micelles of the invention comprise more
specifically at
least one nucleic acid, in particular an oligonucleotide, capable of
modulating gene
expression, a sterol, an acylglycerol, a phospholipid or a sphingolipid, an
alcohol, and
water.
The reverse micelles can be prepared according to a method described below
using at
least a sterol, an acylglycerol, a phospholipid or a sphingolipid, an alcohol
and water.
Said micelles are more particularly obtainable by the following method:
(a) Contacting (i) sterol, preferably sitosterol or cholesterol, (ii)
acyl glycerol, preferably diacylglycerol, (iii) phospholipid, preferably
phosphatidylcholine, or sphingolipid (iv) alcohol, (v) water, preferably
purified
water, and (vi) at least a nucleic acid, in particular an oligonucleotide,
capable of
modulating gene expression,
(b) Stirring mixture obtained in step (a), at 40 C or less, and for a time
sufficient to
obtain formation of reverse micelles.
The parameters of stirring, for instance duration and speed of mechanical
stirring, can
be readily determined by any one skilled in the art and depend on experimental
conditions. In practice, these parameters are such that a microemulsion is
obtained; the
speed is determined so as to enable formation of a visually limpid
formulation, and
duration of the stirring is such that the stirring may be stopped a few
minutes after
obtaining the visually limpid formulation.
In accordance with another broad aspect, the invention relates to a reverse
micelle
system comprising at least one nucleic acid, a sterol, an acylglycerol, a
phospholipid or
CA 2792137 2019-01-15
3a
a sphingolipid, an alcohol and water, wherein the weight ratio phospholipid or
sphingolipid/acylglycerol is from 0.05 to 0.40.
The present invention further relates to a composition comprising reverse
micelles of
the invention and a pharmaceutically acceptable carrier, excipient or support.
DETAILED DESCRIPTION OF THE INVENTION
The following description is of preferred embodiments by way of examples only
and without limitation to the combination of features necessary for
implementing the
invention.
Reverse micelles
The reverse micelle system according to the invention is characterized as a
microemulsion comprising a dispersion of water-nanodroplets in oil. The
dispersion is stabilised by two surfactants (an acylglycerol, more preferably
a
diacylglycerol and a phospholipid, more preferably phosphatidylcholine, or a
sphingolipid) and a co-surfactant (alcohol) that are most likely at the
water/oil interface.
The reverse micelles can be defined as a system wherein water forms the
internal
CA 2792137 2019-01-15
CA 02792137 2012-09-05
W02011/117334 4 PCT/EP2011/054512
phase and the hydrophobic tails of the lipids form the continuous phase.
Reverse micelles containing
oil(s), surfactant(s), co-surfactant(s), and an aqueous phase are also
characterized as water-in-oil
microemulsions. These microemulsions are thermodynamically stable and visually
limpid.
Generally, the size of micelles according to the invention is very small, more
particularly, it is less
than 10 nm; more specifically it is less than 8 nm and more preferably less
than 6 nm. The size may
vary with the quantity of added water and phospholipid or sphingolipid. The
present invention relates
more particularly to reverse micelles with an aqueous core of around 4 nm,
preferably 3 to 5 11111, more
preferably from 3.5 to 5 nm, in particular from 3.7 to 4.5 nm.
The reverse micelles and the size of their aqueous core can be characterized
by various methods,
including:
- Small Angle X-Ray Scattering (SAXS)
- Neutrons Scattering
- Transmission Electron Microscopy (TEM)
- Dynamic Light Scattering (DLS)
The ratios of the lipidic constituents (including sterol, acylglycerol and
phospholipid or sphingolipid)
in the reverse micelle system according to the invention can vary. For
instance, the weight ratio
sterol/acylglycerol can range from 0.015 to 0.05, more particularly from 0.03
to 0.04.
The weight ratio phospholipid or sphingolipid/acylglycerol can range from 0.05
to 0.40, in particular
from 0.06 to 0.25. The weight of phospholipid or sphingolipid respectively
corresponds to the total
weight of the mixture of phospholipids or sphingolipids, for instance the
weight of lecithin, used in the
formulation. Similarly, the weight of acylgylycerol corresponds to the total
weight of the mixture
usually containing an acylglycerol, or a mixture of acylglycerols, with
glycerol and fatty acids derived
from said acylglycerol(s).
The compounds of the reverse micelle system can be analyzed by appropriate
means. More
specifically, sterols can be identified by gas chromatographic analysis and
acylglycerol by high-
performance liquid chromatography (HPLC), in particular with a light
scattering detector, on a silica
column, in the presence of an eluent, e.g. isocratic acetonitrile. Gas
chromatography can also be used
to analyze diacylglycerols. Phospholipids and sphingolipids can be analyzed by
high-performance
liquid chromatography (HPLC), with a diol column with a light scattering
detector.
Reverse micelles are dynamic systems. Brownian motion causes perpetual
collisions of micelles,
which lead to coalescence of micelles and exchange of the aqueous cores.
Separation and regeneration
CA 02792137 2012-09-05
W02011/117334 5 PCT/EP2011/054512
of micelles occur and allow chemical reactions between different solutions.
The exchange rate
between micelles increases in particular with temperature, the length of
hydrocarbon chains of the
surfactant, and the water/surfactant ratio. Within the context of the
invention, aqueous cores of
micelles must have a specific size allowing one or more molecules of nucleic
acid, in particular
oligonucleotide, capable of modulating gene expression, to be stabilised in
the prepared micelles. As
mentioned above, the size of the aqueous core is preferably around 4 mn, more
preferably from 3 to 5
nm, more specifically from 3.5 to 5 nm, in particular from 3.7 to 4.5 nm.
Reverse micelles may exist in the system of the invention as different
structural organizations, such as
spheres, cylinders or branched cylinders for instance.
Without being bound to any theory, it seems that inclusion of a phospholipid
or a sphingolipid in the
reverse micelle system allows formation of stable micelles with greater
diameter and volume, thus
allowing vectorization of greater quantities of nucleic acid. This increase in
vectorized nucleic acid
amounts affords vectorization of sufficient amounts to obtain a therapeutic
activity. The incorporation
of the phospholipid or sphingolipid in the reverse micelle system further
confers a higher stability of
the microemulsions, in particular of the microemulsions containing high
quantities of nucleic acid.
The reverse micelles system of the invention ensures absorption of the
compounds to be delivered
across mucosa, preferably across mouth, nasal and/or rectal mucosa, more
preferably across mouth
mucosa. Also, reverse micelles of the present invention provide an important
bioavailability with low
variability of absorption.
Method for preparing reverse micelles
In a particular embodiment, the invention relates to a method for preparing
reverse micelles presenting
an aqueous core of around 4 nm, preferably from 3 to 5 nm, more preferably
from 3.5 to 5 nm, in
particular from 3.7 to 4.5 nm and involving at least one nucleic acid, in
particular an oligonucleotide,
capable of modulating gene expression, a sterol, an acylglycerol, a
phospholipid or a sphingolipid, an
alcohol, and water, wherein said method comprises the following steps:
(a) Contacting (i) sterol, (ii) acylglycerol, preferably diacylglycerol, (iii)
phospholipid, preferably
phosphatidylcholine, or sphingolipid, (iv) alcohol, (v) water, preferably
purified water, and
(vi) at least a nucleic acid, in particular an oligonucleotide, capable of
modulating gene
expression,
(b) Stirring mixture obtained in step (a), at 40 C or less, and for a time
sufficient to obtain
formation of reverse micelles.
The obtained and recovered reverse micelles are then particularly useful as a
delivery system for
nucleic acids. Step (b) of the process is of particular importance since it
allows reverse micelles to be
CA 02792137 2012-09-05
W02011/117334 6 PCT/EP2011/054512
obtained, said reverse micelles being then useful as a transport system for
delivering the nucleic acid
into the target sites. Target sites may for instance be cells of a specific
tissue.
In a particular embodiment, the nucleic acid is first solubilised in water
(preferably purified water) to
form an aqueous mixture. Said aqueous mixture is then introduced into the oily
mixture (step(a)). The
oily mixture preferably comprises at least a sterol, an acylglycerol, a
phospholipid or a sphingolipid,
and an alcohol.
The compounds involved in step (a) will be described in more details below.
Stirring of the mixture obtained by step (a) is carried out at a temperature
less than or equal to 40 C,
specifically ranging from 15 C to 40 C, or more preferably from 25 C to 40
C, or more specifically
from 30 C to 37 C. The time sufficient can vary in particular upon the used
stirring technique. The
time of stirring is anyhow the time needed to convert the initial mixture into
a visually limpid reverse
micelle solution.
One skilled in the art knows how to select excipients or components that may
be used along with the
composition according to the present invention in order to keep their
beneficial properties. In
particular, the presence of glycerol can, when introduced in large amount,
prevent the formation of
reverse micelles or break the reverse micelle system. More specifically, no
more than 2.5% (percent
expressed by weight of glycerol / weight of acylglycerol) is used for the
preparation of the reverse
micelles of the present invention.
Other compounds can be introduced in step (a). One can cite for instance
colouring agents and/or
flavouring substances.
In an advantageous manner, the compounds cited above or the commercially
available mixtures
containing them are the only ingredients introduced to prepare the micelle
system and consequently
the only ones present in the micelle system of the invention.
Stirring of step (b) may for instance be performed by mechanical stirring.
The common materials may be propellers whose fast movements generate
turbulences and swirls
allowing interpenetration of particles and formation of reverse micelles
within the mixture.
Mechanical stirring speed is preferably ranging from 100 to 2 000 r/minute,
more preferably from 300
to 700 eminute. The implemented volumes, device, and stirring speed depend on
and should be
adapted with the reactants and amounts thereof
Temperature is more specifically ranging from 15 C to 40 C, or from 25 C to
40 C, or even more
specifically from 30 C to 37 C.
CA 02792137 2012-09-05
W02011/117334 7 PCT/EP2011/054512
REVERSE MICELLES COMPOUNDS
ACYLGLYCEROL
Acylglycerols useful for the preparation of the reverse micelle system
according to the invention can
.. be isolated from the majority of animals and more preferably plants.
Acylglycerols include mono-, di and triacylglycerols. In a particular
embodiment, acylglycerols
preferentially used in the present invention present the following formula
(I):
CH2ORi
CHOR2
CH2OR3
(I)
in which:
.. - Rt is an acyl residue of a linear or branched, saturated or unsaturated
fatty acid having between 14
and 24 carbon atoms, a hydrogen atom, or a mono-, di- or tri-galactose or
glucose ;
- R2 is an acyl residue of a linear or branched, saturated or unsaturated
fatty acid having between 2 and
18 carbon atoms;
- R3 is an acyl residue of a linear or branched, saturated or unsaturated
fatty acid having between 14
and 24 carbon atoms, or a hydrogen atom.
According to a particular embodiment, R1 or R3, preferably only one of R1 and
R3, in particular only
RI, represents an acyl residue of oleic acid (C18: 1[cis]-9).
According to a particular aspect, R2 has one unsaturated bond (e.g; ethylenic
bond) and has
advantageously 18 carbon atoms, preferably R2 is an oleic acid residue (oleoyl
group), one of its
positional isomers with respect to the double bond (cis-6,7,9,11 and 13) or
one of its iso-branched
isomers.
According to another particular aspect, R1 represents an oleoyl group.
According to another particular aspect, R2 represents an acetyl group.
According to another particular aspect, R; is a hydrogen atom.
CA 02792137 2012-09-05
W02011/117334 8 PCT/EP2011/054512
As a general rule, oil containing a high concentration of oleic acid will be
chosen as a useful source of
acylglycerols according to the invention. Such oil usually contains a high
proportion of acylglycerols
useful according to the invention.
According to a particular aspect of the invention, the preferred
diacylglycerols are selected in the
group consisting of 1,2-dioleoylglycerol (or also named herein 1,2-diolein)
and 1-oleoy1-2-acetyl
glycerol.
A certain number of them, and more particularly those which are found to be
the most active in the
applications sought after, are also available commercially. This is the case
particularly for 1-oleoy1-2-
acetylglycerol and 1,2-dioleoylglycerol. Glycerol monooleate 40 contains about
33% of
dioleoylglycerol, and about 11 % of 1,2-diolein and is pharmaceutically
accepted (European
Pharmacopeia (4t1 Edition), USP 25/NF20, and Japanese Standard of fOod
Additives). Such product is
for instance commercially available by Gattefosse Company under the name
PECEOC".
The acylglycerols are preferably incorporated or comprised in the composition
or reverse micelle
system in an amount by weight ranging from 50 g to 90 g with respect to 100 g
of the total weight of
the composition or reverse micelle system according to the invention. The
amounts specified herein
will be adapted with respect to the other compounds as to correspond more
specifically to the weight
ratios identified below.
STEROLS
The sterols useful for the preparation of the reverse micelle system according
to the invention are
preferably natural sterols, such as cholesterol or phytosterols (vegetable
sterols). Sitosterol and
cholesterol are the preferred sterols useful for the reverse micelle system
according to the invention.
Sitosterol and cholesterol are commercially available. More particularly,
commercial sitosterol which
is extracted from soya can be used. In such a product, the sitosterol
generally represents from 50 to
80% by weight of the product and is generally found in a mixture with
campesterol and sitostanol in
respective proportions in the order of 15% each. Commercial sitosterol which
is extracted from a
variety of pine called tall oil can also be used. In general, it will be
possible to use sitosterol in mixture
with sitostanol. Preferably, said mixture comprises at least 50% sitosterol by
weight of the mixture.
As mentioned above, the ratios of the lipidic constituents (sterols,
acylglycerol and phospholipids or
sphingolipids) in the reverse micelle system according to the invention can
vary. Preferably, the
weight ratio steroFacylglycerol can range from 0.015 to 0.05, more
particularly from 0.03 to 0.04. The
CA 02792137 2012-09-05
W02011/117334 9 PCT/EP2011/054512
weight of sterol corresponds in the present invention to the total weight of
sterols used in the
formulation, for instance the weight of phytosterol.
The sterols are preferably incorporated or comprised in the composition or
reverse micelle system in
an amount by weight ranging from 0.825 g to 4.5 g with respect to 100 g of the
total weight of the
composition or reverse micelle system according to the invention. The amounts
specified herein will
be adapted with respect to the other compounds as to correspond more
specifically to the weight ratios
identified above and/or below.
PHOSPHOLIPIDS AND SPHINGOLIPIDS
Phospholipids are formed of a glycerol linked to 2 fatty acids and to a
phosphate group. The variability
of phospholipids relies on the fatty acids that are attached to the glycerol
and on the chemical groups
that are susceptible to link to the phosphate group. Phospholipids are, with
sphingolipids, the major
lipidic constituents of biological membranes.
Among phospholipids useful in the present invention may be cited
phosphatidylethanolamine,
phosphatidylscrinc, phosphatidylglyccrol, diphosphatidylglyccrol,
phosphatidylinositol, and
phosphatidylcholine.
In a particular embodiment, the phospholipid is phosphatidylcholine.
Phosphatidylcholine is also
known as 1,2-diacyl-glycero-3-phosphocholine or PtdCho.
Phosphatidylcholine is formed from a choline, a phosphate group, a glycerol
and two fatty acids. It is
actually a group of molecules, wherein the fatty acid compositions varies from
one molecule to
another. Phosphatidylcholine may be obtained from commercial lecithin that
contains
phosphatidylcholine in weight concentrations of 20 to 98%. The lecithin
preferably used for the
preparation of the reverse micelles according to the invention is Epikuron
200A and contains
phosphatidylcholine at a concentration of more than 90%.
Sphingolipids are a class of lipids derived from the aliphatic amino alcohol
sphingosine. Among
sphingolipids that may be used in the present invention may be cited
acylsphingosine, sphingomyelins,
glycosphingolipids, and gangliosides.
The reverse micelles system of the invention may comprise phospholipids,
sphingolipids, or a mixture
of both types of compounds, preferably phospholipids.
According to a specific embodiment, the reverse micelles system of the
invention comprises
phospholipids.
CA 02792137 2012-09-05
WO 2011/117334 10 PCT/EP2011/054512
The weight ratio phospholipid and/or sphingolipid/acylglyccrol in compositions
or reverse micelle
systems according to the invention is from 0.05 to 0.40, preferably from 0.06
to 0.25.
The phospholipids or sphingolipids are preferably incorporated or comprised in
the composition or
reverse micelle system in an amount by weight ranging from 1 g to 30 g,
preferably from 5 to 20 g,
with respect to 100 g of the total weight of the composition or reverse
micelle system according to the
invention. The amounts specified herein will be adapted with respect to the
other compounds as to
correspond more specifically to the weight ratios identified above.
ALCOHOLS
The alcohols useful for the preparation of the reverse-micelle system
according to the invention are
preferably linear or branched mono-alcohols from C2 to C6. Examples of
alcohols are ethanol, 1-
butanol, 2-butanol, 3-methy1-1-butanol, 2-methyl-1-propanol, 1-pentanol, 1-
propanol, 2-propanol and
any mixture thereof. In a particular embodiment of the invention, alcohol is
ethanol.
The alcohol is preferably incorporated or comprised in the composition or
reverse micelle system in an
amount by weight ranging from 5 g to 12 g with respect to 100 g of the total
weight of the composition
or reverse micelle system according to the invention.
WATER
The water useful for the preparation of the reverse-micelle system according
to the invention is
preferably purified water, more preferably RNAse or DNAse-free water.
Water is preferably incorporated or comprised in the composition or reverse
micelle systems in an
amount by weight ranging from 1 g to 15 g, preferably from 5 g to 15 g, with
respect to 100 ml of the
total volume of the composition or reverse micelle system according to the
invention.
One of ordinary skill in the art will adapt the amount of phospholipid or
sphingolipid in the systems to
the desired amount of water. For instance, increasing amount of water should
imply increasing amount
of phospholipid or sphingolipid in the systems.
CA 02792137 2012-09-05
WO 2011/117334 11 PCT/EP2011/054512
NUCLEIC ACIDS
In the present invention, the term "nucleic acid" refers to any nucleic acid
capable of interacting with
mRNA, pre-mRNA or protein and capable of modulating gene expression. Preferred
nucleic acids are
able to up or down regulate the expression of target protein(s).
"Nucleic acid" includes any DNA (deoxyribonucleic acid) and RNA (ribonucleic
acid). The terms
include single-stranded RNA, single-stranded DNA, double-stranded RNA, double-
stranded DNA,
plasmid DNA, isolated RNA such as partially purified RNA, essentially pure
RNA, synthetic RNA,
recombinantly produced RNA, aptamers, as well as nucleic acids comprising non-
standard
nucleotides, such as non-naturally occurring nucleotides or chemically
synthesized nucleotides or
.. deoxynucleotides. One can cite for instance gapmers.
By "oligonucleotide" is meant a nucleic acid comprising from 5 to 100
nucleotides, preferably from 10
to 90 nucleotides, more preferably from 13 to 80 nucleotides, more
particularly from 13 to 25
nucleotides.
The terms "antisense oligonucleotides", "short interfering nucleic acid"
(siNA), "short interfering
.. RNA" (siRNA), "short interfering nucleic acid molecule", "short interfering
oligonucleotide
molecule", "miRNA", "micro RNA", "RNA activation" (RNAa), "short hairpin RNA"
(shRNA), and
"aptamers", as used herein, refer to any nucleic acid molecule capable of
modulating gene expression
by up or down regulating (for instance gene silencing) target protein
expression in a sequence-specific
manner. The various nucleic acid strategies to modulate gene expression are
described below.
1. RNA interference strategy
RNA interference (RNAi) describes a process wherein double-stranded RNA
(dsRNA), when present
inside a cell, inhibits expression of an endogenous gene that has an identical
or nearly identical
sequence to that of the dsRNA (double stranded RNA). Inhibition is caused by
the specific
degradation of the messenger RNA (mRNA) transcribed from the target gene. In
greater detail, RNA
.. interference describes a process of sequence-specific post-transcriptional
gene silencing in animals
mediated by the expression of "short interfering RNAs" (siRNAs) after in situ
cleavage
(Brummelkamp T.R. and al, 2002). The initial basic process involves dsRNA that
is/are processed by
cleavage into shorter units (the so called siRNA) that guide recognition and
targeted cleavage of
homologous target messenger RNA (mRNA).
.. Accordingly, the method does not require time-consuming genetic
manipulations as those needed for
classical gene knock-out strategies and has therefore emerged as a valuable
tool in molecular genetics
that may also be applied to human therapy.
The currently known mechanism of RNAi can be described as follows:
CA 02792137 2012-09-05
WO 2011/117334 12 PCT/EP2011/054512
The processing of dsRNA into siRNAs, which in turn induces degradation of the
intended target
mRNA, is a two-step RNA degradation process. The first step involves a dsRNA
endonuclease
(ribonuclease III-like; RNase ITT-like) activity that processes dsRNA into
smaller sense and antisense
RNAs which are most often in the range of 19 to 25 nucleotides (nt) long,
giving rise to the so called
.. short interfering RNAs (siRNAs). This RNase III-type protein is termed
"Dicer". In a second step, the
antisense siRNAs produced combine with, and serve as guides for, a different
ribonuclease complex
called RNA-induced silencing complex (RISC), which allows annealing of the
siRNA and the
homologous single¨stranded target mRNA, and the cleavage of the target
homologous single-stranded
mRNAs. Cleavage of the target mRNA has been observed to place in the middle of
the duplex region
complementary to the antisense strand of the siRNA duplex and the intended
target mRNA
(Dykxhoorn D.M. and al, 2003).
A siRNA alternative is a plasmid coding for hairpin siRNA, which is called
shRNA strategy (small
hairpin RNA). In the cell, hairpin RNA is generated and interacts with the
DICER protein, resulting in
a functional siRNA which will be incorporated in the RISC complex and acting
like a classical siRNA
(Wacheck V. and Zangemeister-Wittke U., 2006). The transfection with such
plasmids allows
numerous copies of shRNA and of endogenous siRNA molecules (McCaffrey A. P.
and al, 2002).
Micro RNAs (miRNAs) are non coding RNAs of 21 to 25 nucleotides, controlling
genes expression at
post-transcriptional level. miRNAs are synthesized from RNA polymerase II or
RNA polymerase III
in a pre-miRNA of 125 nucleotides. Pre-miRNA are cleaved in the nucleus by the
enzyme Drosha,
giving rise to a precursor called imperfect duplex hairpin RNA (or miRNA-based
hairpin RNA).
These imperfect duplex hairpin RNAs are exported from the nucleus to the
cytoplasm by exportin-5
protein, where it is cleaved by the enzyme DICER, giving rise to mature
miRNAs. miRNAs combine
with RISC complex which allows total or partial annealing with the homologous
single-stranded target
mRNA. Partial annealing with the mRNA leads to the repression of protein
translation, whereas total
.. annealing leads to cleavage of the single-stranded mRNA (Dykxhoorn D.M. and
al, 2003 for review).
By "antisense strand" is meant a nucleotide sequence of a siRNA molecule
having complementarity to
a sense region of the siRNA molecule. In addition, the antisense strand of a
siRNA molecule
comprises a nucleic acid sequence having homology with a target nucleic acid
sequence.
By "sense strand" is meant a nucleotide sequence of a siRNA molecule having
complementarity to an
antisense region of the siRNA molecule.
By "modulate" and "modulation" is meant that the expression of the gene, or
level of RNA molecule
or equivalent RNA molecules encoding one or more proteins or protein subunits,
or activity of one or
more proteins or protein subunits is up regulated or down regulated, such that
expression, level, or
activity is greater than or less than that observed in the absence of the
modulator. Within the scope of
CA 02792137 2012-09-05
WO 2011/117334 13 PCT/EP2011/054512
the invention, the preferred form of modulation is inhibition, but the use of
the word "modulate" is not
limited to this definition.
By "inhibit", "silence" or "down regulate" it is meant that the levels of
expression product or level of
RNAs or equivalent RNAs encoding one or more gene products is reduced below
that observed in the
absence of the nucleic acid molecule of the invention. In one embodiment,
inhibition with a nucleic
acid molecule capable of mediating RNA interference (siRNA, shRNA, miRNA)
preferably is below
that level observed in the presence of an inactive or attenuated molecule that
is unable to mediate an
RNAi response.
By "target protein" is meant any protein whose expression or activity is to be
modulated.
By "target nucleic acid" or "target gene" is meant any nucleic acid sequence
whose expression or
activity is to be modulated. The target nucleic acid can be for instance DNA
or RNA.
The nucleic acid capable of modulating gene expression includes, but is not
limited to, "short
interfering nucleic acid" (siNA), "short interfering RNA" (siRNA), "short
interfering nucleic acid
molecule", "short interfering oligonucleotide molecule", "miRNA", "micro RNA"
and "short hairpin
RNA" (shRNA), as defined above.
2. Antisense strategy.
a. Classical antisense strategy.
Antisense strategy is a special and rational strategy based on the
oligonucleotide chemical
modification and which purpose is to inhibit specifically gene expression,
with antisense
oligonucleotides (ASON) complementary of the target RNA sequence, resulting in
an inhibition of the
protein expression. ASON are considered since 1978 as a new class of drugs
capable of silencing
specifically genes implicated in diseases (Gallo M. and al, 2003, Chan J.H.
and al, 2006).
ASON is a single-stranded deoxyribonucleotide (DNA) or ribonucleotide (RNA) of
13 to 25,
preferably 15 to 21, bases. Hybridization of the ASON on the target mRNA leads
to the translation
stop by steric-blocking, to its destruction by recruitment of the
intracellular RNase H, which role is to
cleave the DNA / RNA duplex, or to destabilize the pre-mRNA, resulting in a
splicing inhibition
(Kuffeck J.,2003 ; Chan J.H. and al, 2006).
b. New applications for antisense oligonucleotides.
In several recent applications, the ASON is not used to inhibit a gene
expression, but on the contrary
to restore a normal protein synthesis. In alternative splicing correction and
exon skipping models, the
alternative splicing is abnormal. In general, an aberrant mutation located at
an intron (splicing
CA 02792137 2012-09-05
WO 2011/117334 14
PCT/EP2011/054512
correction) or exon (exon skipping) locus, is at the origin of an abnormal
splicing, resulting in a non-
functional protein responsible for the disease symptoms (Kang S.H. and al,
1998 ; Sazani P. and Kole
R., 2003).
ASON is capable to hybridize specifically at the mutation locus, in a sequence-
dependant manner,
masking the mutation and reorienting the machinery towards a normal
alternative splicing with the
expression of the functional protein.
These applications have a huge interest in the treatment of several cancers,
neurologic diseases such as
Huntington's disease, age related macular disease and genetic diseases such as
P-Thalassemia,
Duchenne Muscular Distrophy (DMD), Hutchinson Gilford Progeria Syndrome (HGPS)
or Cystic
Fibrosis (CF) for the CFTR mutation (Mercatante D.R. and al, 2001 ; Srebrow A
and Kornblihtt A.R..
2006 ; Brinkman B.M.,. 2004, and Venables J.P., 2006).
c.
Chemical modifications and new generations of antiscnse oligonucleotidcs.
Efforts have been realised to modify chemical ASON structure, so that the
RNase H could not degrade
the duplexes of nucleic acids during the hybridation of the ASON on the RNA
strand: structural
modifications at the ribose level (2'-fluoro, 2'-methyl, 2'-methoxy), at the
base level and at the
backbone level (phosphodicstcr, phosphorithioatc).
ASON with chemical modification structure of the second (2'-0-methyl, 2'-0-
methoxyethyl or MOE)
and third (locked nucleic acid or LNA, peptide nucleic acid or PNA,
phosphoamidate morpholino or
PMO) generation, not activator of the RNase H enzyme, are preferred (Altmann
K.H. and al, 1996,
Egholm M. and al, 1993; Singh S.K. and al, 1998, Summerton J. and Weller D.,
1997).
Gapmers are chimeric antisense oligomers (mix of RNA and DNA nucleotides) with
a short strech of
phosphorothioate DNA (5-12 nucleotides). They have been used to obtain RNAse H
mediated
cleavage of target RNA and mRNA degradation. In addition to high ASO potency,
they improve target
accessibility and nuclease resistance (Kurreck J., 2003).
By "antisense oligonucleotide" is meant a single-stranded oligonucleotide
capable of specific
hybridization with the mRNA (in the cell cytoplasm) or the pre-mRNA (in the
cell nucleus).
The nucleic acid capable of mediating antisense mechanism includes, but is not
limited to, single-
stranded DNA oligonucleotides, single-stranded RNA oligonucleotides,
unmodified and chemically
modified oligonucleotides.
15
3. Aptamers.
Aptamers are 20 to 80 nucleotides nucleic acids, composed of DNA, RNA or
chemically modified
nucleotides (2'-fluoro, 2'-0-methyl or phosphorothioate) (Chan J.H. and al,
2006). Thanks to their 3D
structure, aptamers are able to bind to various molecules and proteins with a
high affinity, via Van der
Walls, hydrogen and electrostatic bounds (Pendergrast P.S. and al, 2005).
The most interested application of aptamers appears to be regulation of gene
expression by inhibiting
protein activity.
High affinity aptamers can be obtained by the SELEX technology (Systematic
Evolution of Ligands
by Exponential Enrichment), developed in 1990. A pool of oligonucleotides (10"
to 10" different
sequences) is mixed with the target and only those linked to the target are
selected. These aptamers are
then amplified and used in the following cycle. After 5 to 15 amplifications
steps, high affinity
aptamers are obtained (Rimmelle M., 2003; Chauveau F. and al, 2006). This
technique is now
robotized.
Due to their lack of immunogenicity, aptamers seem to be good candidates for
therapeutic applications
in autoimmune diseases (White R.R. and al, 2000 ; Kim Y.M. and al, 2003 ;
Drolet D.W. and al.,
Pharmacokinetics and safety of an anti-vascular endothelial growth factor
aptamer (NX1838)
following injection into the vitreous humor of rhesus monkeys, Pharm Res,
2000, 17(12):1503-10 ; and
Rhodes A. and al, 2000).
Such agents incorporated in the reverse micelle system according to the
invention can cross mucosal
epithelial barriers and present thereby its therapeutic effect at the target
sites.
The nucleic acids capable of modulating gene expression are present in the
aqueous core of the reverse
micelles.
Stability and activity of the therapeutic agent can be controlled essentially
by water concentration in
the mixture.
The amount of the nucleic acid capable of modulating gene expression
incorporated into the reverse
micelle system is determined by their solubility in the hydrophilic phase
(aqueous core). Preferably,
the amount of therapeutic agent included in the reverse micelle system depends
on the size of the
nucleic acid capable of modulating gene expression.
In the present invention, the weight concentration of the nucleic acid in the
microemulsion is more
specifically calculated with a density of 0.94 +/-0.03 for the microemulsion.
The density is generally measured at room temperature and atmospheric
pressure.
CA 2792137 2018-05-16
CA 02792137 2012-09-05
WO 2011/117334 16 PCT/EP2011/054512
REVERSE MICELLE SYSTEM AND USE THEREOF
The reverse micelles of the invention allow the nucleic acid included therein
to be administered and
transported to cells with a high degree of protection, in particular without
affecting its stability.
It is known today that a reverse micelle system can be used for the
preparation of nanomaterials,
which act as micro reactors. The activity and stability of bio molecules can
be controlled, mainly by
the concentration of water in the reverse micelle system.
An object of the invention concerns a pharmaceutical composition comprising
reverse micelles as
defined above and at least a pharmaceutically acceptable carrier, excipient or
support.
According to a specific embodiment, the pharmaceutical composition according
to the invention
comprises from 5 to 20 g of phospholipid or sphingolipid with respect to 100 g
of composition, and
from 5 to 15 g of water with respect to 100 ml of composition.
According to a particular embodiment, the pharmaceutical composition is in the
form of a capsule, a
caplet, an aerosol, a spray, a solution or a soft elastic gelatin capsule. A
further object of the invention
concerns the use of reverse micelles as defined above for preparing a
pharmaceutical composition
intended for the delivery, more specifically the mucosal delivery, of one or
more nucleic acids. The
pharmaceutical composition is more particularly intended to prevent, treat,
and/or improve the
symptoms of genetic diseases, cancers, neurodegenerative diseases, infectious
and/or inflammatory
diseases, diseases or disorders due to cell proliferation.
Another object of the invention concerns a method for the delivery of one or
more nucleic acids to a
mammal (in particular human), said method comprising administering the reverse
micelle composition
as defined above to the mammal. In a specific embodiment, the present
invention provides a method
for the mucosal delivery of one or more nucleic acids, said method comprising
mucosally
administering to said mammal (in particular human) a reverse micelle
composition as defined above.
The present invention provides a method for the prevention, treatment, and/or
improvement of the
symptoms of a genetic disease, cancer, neurodegenerative disease, infectious
and inflammatory
disease or a disease due to cell proliferation, said method comprising
administering to said human in
need thereof an effective amount of a reverse micelle composition as defined
above and comprising
one or more nucleic acids useful in the prevention, treatment or improvement
of the symptoms of the
genetic disease, cancer, neurodegenerative disease, infectious and
inflammatory disease or disease due
to cell proliferation. In a specific embodiment, the present invention
provides a method for the
prevention, treatment or improvement of one or more symptoms associated with a
disease or disorder
as defined above, said method comprising mucosally administering to a subject
in need thereof an
effective amount of a reverse micelle composition as defined above and
comprising one or more
CA 02792137 2012-09-05
WO 2011/117334 17 PCT/EP2011/054512
nucleic acids useful in the prevention, treatment or improvement of one or
more symptoms associated
with said disease or disorder.
As pharmaceutically acceptable excipient, vehicle or carrier, any excipient,
vehicle or carrier well-
known to the person skilled in the art may be used. Other additives well-known
to the person skilled in
the art such as stabilisers, drying agents, binders or pH buffers may also be
used. Preferred excipients
in accordance with the invention promote adherence of the finished product to
the mucosa.
The present invention further concerns the use of a pharmaceutical composition
as described above for
the delivery of at least a nucleic acid to a mammal, said delivery comprising
mucosal administration of
the pharmaceutical composition.
In a specific embodiment, the pharmaceutical composition of the invention is
used for the delivery,
more specifically the mucosal delivery, of at least a nucleic acid.
Nucleic acids in reverse micelle system formulated according to the invention
are preferably able to
cross the blood brain barrier. Consequently, they can be useful in the
treatment of central nervous
sytem (CNS) disorders, in particular genetic, tumoral, viral and/or
degenerative diseases in the CNS.
The compositions of the invention can be administered in different ways, in
particular via mucosal
tissue absorption, with a buccal, nasal, vaginal or digestive absorption.
"Subject" refers to an organism to which the nucleic acid of the invention can
be administered. The
subject may be a non-human animal, preferably a mammal. The prefeued subject
is a human subject.
As used herein, the terms "mucosa'' and "mucosal" refer to a mucous tissue
such as of the respiratory,
digestive, or genital tissue. ''Mucosal delivery", "mucosal administration"
and analogous terms as used
herein refer to the administration of a composition through a mucosal tissue.
"Mucosal delivery",
"mucosal administration" and analogous terms include, but are not limited to,
the delivery of a
composition through bronchi, gingival, lingual, nasal, oral, vaginal, rectal,
and gastro-intestinal
mucosal tissue.
In a preferred embodiment of the invention, the reverse micelle composition of
the invention is
mucosally administered as a capsule, a caplet, an aerosol, a spray, a
solution, or a soft elastic gelatin
capsule. The compositions of the invention can for instance be introduced in
liquid form into capsules
which release their contents in the mouth or on any mucous tissue. Preferably,
the reverse micelle
compositions of the invention are administered to a mammal, more preferably a
human, to treat a
disease or disorder, such as a genetic disease, cancer, neurodegenerative
disease, infectious and
inflammatory disease or a disease due to cell proliferation.
CA 02792137 2012-09-05
WO 2011/117334 18 PCT/EP2011/054512
The following examples are intended to exemplify the operation of the present
invention but not to
limit its scope.
DESCRIPTION OF THE FIGURES
Figure 1: Evaluation of the impact of the rate of incorporated water in
absence of lecithin on
diffraction curves (fig la) and size (fig lb) of reverse micelles.
Figure 2: Evaluation of the impact of the rate of incorporated water in
presence of lecithin on
diffraction curves (fig 2a) and size (fig 2b) of reverse micelles.
Figure 3: Evaluation of the impact of incorporated GAPDH siRNA content on
diffraction curves
of reverse micelles.
Figure 4: In vivo biodistribution of naked Alexa 700-C1B1 siRNA (Fig 4a)
and Alexa 700-C1B1
siRNA formulated in reverse micelles (Fig 4b).
Figure 5: In vivo evaluation of liver GAPDH gene inhibition.
Figure 6: In vivo evaluation of muscle MAFBx gene inhibition.
Figure 7: In vivo evaluation of liver PCSK9 protein inhibition.
Figure 8: In vivo evaluation of brain PrP(C) protein inhibition.
EXAMPLES
Example 1: Evaluation of water incorporation impact on formation and size of
reverse micelles
in absence of lecithin
The aim of this study was to evaluate by X ray diffraction method and visual
determination the impact
of water content on the formation of thermodynamically stable microemulsions
and the size of reverse
micelles dispersed therein.
10 formulations of reverse micelles with different percentages of water were
prepared according to the
procedure below.
0.7 g of phytosterol were dissolved in 1.4 g of absolute ethanol by magnetic
stirring at 300 r/min for
15 minutes at 37 C. Glycerol monooleate was added thereto and magnetic
stirring was carried out at
CA 02792137 2012-09-05
WO 2011/117334 19 PCT/EP2011/054512
500 r/min for 45 minutes at 37 C. Purified water was added to this oil mixture
and stirred between 300
and 500 rimin for 60 minutes at 37 C to form "empty- reverse micelles.
The different formulations are summarized in the table below.
Sample Water content (/o) Glycerol
monooleate Water
1 258g 0.3 g
2 2 25.5 g 0.6 g
3 3 25.2g 0.9g
4 4 24.9g 1.2 g
5 24.6g 1.5g
6 6 24.3g 1.8g
7 7 24.0g 2.1 g
8 8 23.7g 2.4g
9 9 23.4g 2.7g
10 23.1 g 3.0 g
5 "Empty" reverse micelles were prepared by increasing quantity of water
from 1% to 10% with
increment of 1% (the percentage of water is expressed by weight of water/total
volume of the
composition, density of 0.94). The percentage of absolute ethanol (5%) and
phytosterol (2.5%)
(weight/total weight of the composition) were unchanged for all these
products.
The formation of thermodynamically stable microemulsions was evaluated by the
visual determination
10 of their limpidity.
Lattice parameters are obtained by X-ray diffraction and they are assumed to
correspond to the size of
reverse micelles of the invention. Samples were introduced in 1.5 mm diameter
glass capillaries and a
transmission configuration was used. A cupper rotating anode X-Ray source
(functioning at 4kW)
with a multilayer focusing "Osmie" monochromator giving high flux (108
photons/sec) and punctual
collimation were employed. An "Image plate" 2D detector was used. Diffraction
curves were obtained
giving diffracted intensity as a function of the wave vector q. Diffracted
intensity was corrected by
exposition time, transmission and intensity background coming from diffusion
by an empty capillary.
Reverse micelle sizes were calculated with the formula: d = 2 7c/lqmax (q max
is the wave vector
corresponding to the maximal diffracted intensity).
Diffraction curves of 10 samples prepared according to above procedure are
shown in figure la, which
clearly demonstrates that between 1% and 6% of incorporated water, the qmax
value decreases when
the percentage of water increases. Figure lb shows that between 1% and 6% of
incorporated water, the
CA 02792137 2012-09-05
WO 2011/117334 20 PCT/EP2011/054512
size of reverse micelles increases from 3.1 to 3.7 rim when the percentage of
water increases. In
contrast, from 7% of incorporated water, the size of reverse micelles stops
increasing.
Furthermore, the visual analysis shows that from 1 to 5 % of incorporated
water, the products are
limpid. From 6% of water, the products become more and more turbid.
These results clearly show that formulations formed in absence of lecithin are
unstable over a certain
amount of water (6%). They additionally show that the micelles formulated
without lecithin cannot
exceed a given size even when increasing the amount of water in the
formulation.
Example 2: Evaluation of water incorporation impact on formation and size of
reverse micelles
in presence of lecithin
The aim of this study was to evaluate by X ray diffraction method and visual
deteimination the impact
of water content on the formation of thermodynamically stable microcmulsion
and the size of reverse
micelles dispersed therein in presence of increasing rate of lecithin.
3 formulations of reverse micelles with different percentages of water and
lecithin were prepared
according to the procedure below.
Commercially available lecithin was dissolved in 8.5 g absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 2.3 g of phytostcrol were added to
the mixture and stirred in
the same conditions. Glycerol monooleate was added thereto and magnetic
stirring was carried out at
500 r/min for 45 minutes at 37 C to form an oil mixture. Purified water was
added to the oil mixture
and stirred at room temperature by magnetic stirring between 300 and 500 r/min
for 30 minutes to
form "empty" reverse micelles.
The different formulations are summarized in the table below
Sample Lecithin Glycerol monooleate Water Oil
mixture
11 0 g (0%) 79.3 g 20.4 mg (4%) 453.9 mg
12 9.4 g (10%) 64.8 g 45.0 mg (9%) 433.8 mg
13 14.1 g (15%) 57.0 g 60.0 mg (12%) 423.3 mg
"Empty" reverse micelles were prepared by varying amount of water from 4%
(sample 11) to 12%
(sample 13) and lecithin from 0% (sample 11) to 15% (sample 13). Lecithin
content is calculated from
weight of lecithin/total weight of the composition and water content from
weight of water/total volume
CA 02792137 2012-09-05
WO 2011/117334 21 PCT/EP2011/054512
of the composition (density of 0.94). The percentage of phytostcrol was 2.5%
(weight of
phytosterol/total weight of the composition) and that of absolute ethanol was
9% (weight of absolute
ethanol/total weight of the composition) for all these samples.
The formation of thermodynamically stable microemulsions was evaluated by the
visual determination
.. of their limpidity.
The size of reverse micelles of these formulations was evaluated by X-ray
diffraction experiments as
described in example 1.
Diffraction curves of samples 11, 12, and 13 are shown in figure 2a which
clearly demonstrates that
the diffracted intensity increases and the qmax value decreases when the
percentage of lecithin
.. increases from 0 to 15%. Figure 2b demonstrates that the size of reverse
micelles increases from 3.1 to
4.5 nm when the percentage of lecithin increases from 0 to 15%. The visual
analysis shows that these
formulations are limpid.
Consequently, these experiments show that the addition of 15 % of lecithin
allows the formation of
thermodynamically stable microemulsions with reverse micelle size of 4.5 nm
and high percentages of
water (12%). Addition of lecithin thus solves the drawbacks of reverse
micelles formulated in absence
of lecithin described in example 1.
Example 3: Evaluation of GAPDH siRNA incorporation impact on formation and
size of reverse
micelles
The aim of this study was to evaluate by X ray diffraction method and visual
determination the impact
of GAPDH siRNA content on the formation of thermodynamically stable
microemulsions and the size
of reverse micelles dispersed therein in presence of lecithin.
GAPDH siRNA is a double stranded siRNA comprising 21 nucleotides and designed
to allow gene
silencing of GAPDH gene.
4 formulations of reverse micelles with different concentrations of GAPDH
siRNA were prepared
according to the procedure below.
A siRNA solution containing GAPDH siRNA was added to the oil mixture prepared
according to
sample 13 and stirred at room temperature by magnetic stirring between 300 and
500 r/mM for 30
minutes to form reverse micelles containing GAPDH siRNA.
The different formulations are summarized in the table below:
CA 02792137 2012-09-05
WO 2011/117334 22 PCT/EP2011/054512
siRNA solution or
Sample GAPDH siRNA Oil mixture GADPH concentration
water
A 59.6 mg 150 jig 4113 ma
= 300 ilig/m1
60.9 mg 228 lug 414 8 ma
= 450 ig/m1
61.1 mg 303 jig 414 5 ma
= 600 lig/m1
59.9 mg 479 lag 413 2 ma
- 950 lag/m1
13 60.0 mg 0 j.tg 423 3 ma
= 0 Kg/m1
Reverse micelles were prepared by increasing concentrations of GAPDH siRNA
from 0 (sample 13) to
950 ig/m1 (sample D). The percentage of phytosterol was 2.5% (weight of
phytosterol/total weight of
the composition), that of absolute ethanol was 9% (weight of absolute
ethanol/total weight of the
composition), that of water was 12% (weight of water/total volume of the
composition, density of
0.94) and that of lecithin was 15 % (weight of lecithin/total weight of the
composition) for all these
samples.
The formation of thermodynamically stable microcmulsions was evaluated by the
visual determination
of their limpidity.
The size of reverse micelles of these formulations was evaluated by X-ray
diffraction experiments as
described in example 1.
Figure 3 shows diffraction curves of samples 13, A, B, C and D. The (pica
value is the same for all
the samples in spite of an increase of GAPDH siRNA concentration. The reverse
micelle size is
calculated at 4.5 nm for all these samples. The visual analysis shows that
these formulations are
limpid.
These experiments show that the addition of GAPDH siRNA does not disturb the
formation of
thermodynamically stable microemulsions and does not change the size of
reverse micelles dispersed
therein.
Example 4: Evaluation of in vivo biodistribution of fluorescent Alexa 700-
Cyclin B1 (C1B1)
siRNA formulated in reverse micelles
The aim of this study was to evaluate by animal imaging technique the
biodistribution of Alexa 700-
C1B1 siRNA formulated in reverse micelles according to the procedure below
(sample E) when
delivered by rectal route compared to same dosage of unformulated said siRNA
in solution delivered
by intravenous route.
CA 02792137 2012-09-05
WO 2011/117334 23 PCT/EP2011/054512
Alexa 700-C1B1 siRNA is a double stranded siRNA comprising 21 nucleotides and
designed to be
fluorescent.
Sample E: 14.1 g of lecithin were dissolved in 8.5 g absolute ethanol by
magnetic stirring at 300 r/min
for 10 minutes at room temperature. 2.3 g of phytosterol were added to the
mixture and stirred in the
same conditions. 57.0 g of glycerol monooleate were added thereto and magnetic
stirring was carried
out at 500 r/min for 45 minutes at 37 C. 48 mg of a siRNA solution containing
100 lug of Alexa 700-
C1B1 siRNA were added to 328.7 mg of the oil mixture and stirred at room
temperature by magnetic
stirring at 700 r/min for 45 minutes to form reverse micelles containing 250
lag Alexa 700-C1B1
siRNA/m1 (density of 0.94).
.. Administered products:
- Sample E: reverse micelles prepared according to above procedure at 250
lag Alexa 700-C1B1
siRNA/ml, delivered at 2 ml/kg by rectal route
- Unformulated Alexa 700-C1B1 siRNA: naked siRNA in solution at 50 jig
Alexa 700-C1B1 siRNA
/ml, delivered at 10 mag by intravenous route
Unformulated naked Alexa 700-C1B1 siRNA or reverse micelles formulated with
said siRNA were
administered once at 500 lag/kg (10 lug) in anesthetised nude mice. Naked
Alexa 700-C1B1 siRNA
solution was administrated intravenously in the tail vein and reverse micelles
formulated siRNA were
administrated slowly with a pipette into the lower rectum, immediately after
the anal sphincter.
Mice were placed under camera at 660 nm and side and ventral pictures were
taken at 0, 15 min, lh,
2h, 4h, 5h and 24h to visualize fluorescence intensity biodistribution.
Results are shown in figures 4a and 4b. Figure 4a demonstrates a rapid
absorption of naked siRNA
after iv injection. The maximal fluorescence intensity is observed 15 minutes
post-administration and
decreased rapidly.
In contrast, the figure 4b shows that siRNA formulated in reverse micelles and
administered by rectal
route, is widely distributed in the entire body of the animal with a
fluorescence peak at around 4 hours
and a very slow elimination.
The above experiment demonstrates that siRNA formulated in reverse micelles
can be delivered in
Iwo and that the reverse micelles formulation highly increases siRNA
protection and life span.
CA 02792137 2012-09-05
WO 2011/117334 24 PCT/EP2011/054512
Example 5: Evaluation of in vivo efficacy of GAPDH siRNA formulated in reverse
micelles
formulations to inhibit GAPDH gene expression
The aim of this study was to evaluate liver GAPDH gene silencing efficacy of
GAPDH siRNA
formulated in reverse micelles prepared according to the procedures below
(samples F and G) when
delivered by rectal route in C57B1/6J mice.
GAPDH siRNA is a double stranded siRNA comprising 21 nucleotides and designed
to allow gene
silencing of GAPDH gene.
Sample F: 2.3 g of cholesterol were dissolved in 8.5 g of absolute ethanol by
magnetic stirring at 300
r/min for 15 minutes at room temperature. 79.2 g of glycerol monooleate were
added thereto and
magnetic stirring was carried out at 500 r/min for 45 minutes at 37 C to form
oil mixture. 40.0 mg of a
siRNA solution containing 301 jig of GAPDH siRNA were added to 904.0 mg of the
oil mixture and
stirred at room temperature by magnetic stirring between 300 and 500 r/min for
30 minutes to form
reverse micelles containing 300 jig GAPDH siRNA/m1 (density of 0.94).
Sample G: 6.6 g of lecithin were dissolved in 8.5 g of absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 2.3 g of cholesterol were added to
the mixture and stirred in
the same conditions. 67.7 g of glycerol monooleate were added thereto and
magnetic stirring was
carried out at 500 r/min for 45 minutes at 37 C. 45.2 mg of a siRNA solution
containing 286 jig of
GAPDH siRNA were added to 852.7 mg of the oil mixture and stirred at room
temperature by
magnetic stirring between 300 and 500 r/min for 30 minutes to form reverse
micelles containing 300
lag GAPDH siRNA/m1 (density of 0.94).
Sample 14: 40.5 mg of purified water was added to 900.6 mg of the oil mixture
prepared according to
sample F and stirred at room temperature by magnetic stirring between 300 and
500 r/min for 30
minutes to form "empty" reverse micelles.
Administered products:
- Sample F: reverse micelles prepared according to above procedure at 300 us
GAPDH siRNA/ml,
delivered at 1 ml/kg by rectal route for 3 days
- Sample G: reverse micelles prepared according to above procedure at 300
jig GAPDH siRNA/ml,
delivered at 1 ml/kg by rectal route for 3 days
- Sample 14: "empty" reverse micelles prepared according to above
procedure, delivered at 1 ml/kg
by rectal route for 3 days
CA 02792137 2012-09-05
WO 2011/117334 25 PCT/EP2011/054512
As described in table below, both formulations of reverse micelles containing
GAPDH siRNA were
delivered at 600 Kg/kg (300 11g/kg twice a day) for 3 days in C57B1/6J mice
(groups 2 and 3, 3 mice
per group). These products were delivered slowly with a pipette into the lower
rectum, immediately
after the anal sphincter. Mice untreated or treated with "empty" reverse
micelles were used as controls
(groups 1 and 4) (sample 14).
Mice were sacrificed 24 hours after the last administration. Livers were then
harvested and frozen.
Total RNA was extracted by TRIzorichloroforrn method and GAPDH mRNA expression
was
evaluated by quantitative RT-PCR, relative to a normalizer gene (ubiquitin).
Results are shown in figure 5 which demonstrates the in vivo efficacy of GAPDH
siRNA formulated
in reverse micelles containing cholesterol (sample F) to reduce liver GAPDH
gene expression. The
addition of lecithin in sample G shows similar efficacy to reduce GAPDH gene
expression. In
contrast, the "empty" reverse micelles (sample 14) are ineffective at
decreasing GAPDH gene
expression. Reverse micelles according to the invention are thus as efficient
as those not containing
lecithin for delivery of such quantities of nucleic acids. They additionally
allow delivery of greater
amounts of nucleic acids than reverse micelles without lecithin.
Animal Delivered volume
Groups Treatment Delivered dose (pg/kg/d)
Number (ml/kg/d)
1 3 No treatment 0
2 3 Sample F 600 2x 1
3 3 Sample G 600 2x 1
4 3 Sample 14 0 2x1
Example 6: Evaluation of in vivo efficacy of Ubiquitin ligase Atrogin 1/Muscle
Atrophy F-box
sequence (MAFbx) siRNA formulated in reverse micelles to inhibit MAFbx gene
expression
The aim of this study was to evaluate MAFbx gene silencing efficacy of MAFbx
sil or si2 siRNA
formulated in reverse micelles according to the procedures below (samples H
and I) when delivered
by rectal route compared to same dosage of unformulated MAFbx sil siRNA
delivered intravenously,
in an induced mice model of MAFbx over expression.
MAFbx sil and si2 siRNA are double stranded siRNAs respectively comprising 19
and 21 nucleotides
and designed to allow gene silencing of MAFbx gene.
Sample H: 14.1 g of lecithin were dissolved in 8.5 g absolute ethanol by
magnetic stirring at 300
r/min for 10 minutes at room temperature. 2.3 g of phytostcrol were added to
the mixture and stirred in
the same conditions. 57.0 g of glycerol monooleate were added thereto and
magnetic stirring was
CA 02792137 2012-09-05
WO 2011/117334 26 PCT/EP2011/054512
carried out at 500 r/min for 45 minutes at 37 C. 117.3 mg of a siRNA solution
containing 303 jig of
MAFBx sl siRNA were added to 833.8 mg of the oil mixture and stirred at room
temperature by
magnetic stirring between 300 and 500 r/min for 30 minutes to form reverse
micelles containing 300
jig MAFbx sil siRNA/m1 (density of 0.94).
Sample I: 2.3 g of phytosterol were dissolved in 8.5 g of absolute ethanol by
magnetic stirring at 300
r/min for 15 minutes at room temperature. 79.2 g of glycerol monooleate were
added thereto and
magnetic stirring was carried out at 500 r/m for 45 minutes at 37 C to form
oil mixture. 39.5 mg of a
siRNA solution containing 302 jig of MAFbx si2 siRNA were added to 905.4 mg of
the oil mixture
and stirred at room temperature by magnetic stirring between 300 and 500 r/min
for 30 minutes to
form reverse micelles containing 300 jig MAFbx si2 siRNA/m1 (density of 0.94).
Administered products:
- Sample H: reverse micelles prepared according to the above procedure at
300 jig MAFbx sil
siRNA/ml, delivered at 1 mlikg by rectal route on days 1 and 2
- Sample I: reverse micelles prepared according to the above procedure at
300 jig MAFbx si2 siRNA
/ml, delivered at 1 ml/kg by rectal route on days 1 and 2
- Unformulated MAFbx sil siRNA: naked siRNA in solution at 300 jig/ml,
delivered at 1 ml/kg by
intravenous route on day 1 and at 150 jig/ml delivered at 1 ml/kg the second
day.
B6CBA Fl mice were treated as described in table below. Reverse micelles
formulated with MAFbx
sil or 2 siRNA (samples H and I) were delivered at 300 jig/kg by rectal route
once a day for 2 days.
These products were delivered slowly with a pipette into the lower rectum,
immediately after the anal
sphincter. Following this treatment, a 2 days starvation for food was applied
to induce skeletal
muscular atrophy and overexpression of MAFbx (groups 5 and 7, 8 mice per
group). Mice
administered with the same treatment (samples H and I) but not starved were
used as controls (groups
4 and 6, 4 mice per group). Another group of 8 mice (group 3) was treated with
unformulated naked
MAFbx sil siRNA by intravenous route in the tail vein at 300 jig/kg the first
day and 150 jig/kg the
second day followed by a 2 days food starvation. Untreated mice starved or not
for food, were used as
controls (groups 1 and 2, 8 mice per group).
All mice were sacrificed on day 5, and Tibia/is Anterior (TA) muscles were
harvested and frozen.
Total RNA was extracted by TRIzor/chloroform method and MAFbx mRNA expression
was
evaluated relative to normalizer ribosomal gene (RPS9) by quantitative RT-PCR
using mini Opticon
Real Time PCR system (Biorad).
Results of quantitative PCR are shown in figure 6, which clearly demonstrates
the efficacy of reverse
micelles formulated with MAFbx siRNA to reduce the MAFbx gene overexpression.
Around 90%
CA 02792137 2012-09-05
WO 2011/117334 27
PCT/EP2011/054512
reduction in MAFbx mRNA levels is observed in animal treated with samples H
and 1 compared to
untreated animal. Reverse micelles according to the invention are thus as
efficient as those not
containing lecithin for delivery of such quantities of nucleic acids. They
additionally allow delivery of
greater amounts of nucleic acids than reverse micelles without lecithin.
Delivered
Delivered
Animal Active
Groups Animal type Treatment dose
volume
Number compounds
(tg/kg/d)
(ml/kg/d)
No food
1 8 No treatment 0
deprivation
Food
2 8 No treatment 0
deprivation
Food Naked MAFbx sil
3 8 300 and 150 1
deprivation siRNA siRNA
No food MAFbx sil
4 4 Sample H 300 1
deprivation siRNA
Food MAFbx sil
8 Sample H 300 1
deprivation siRNA
No food MAFbx si2
6 4 Sample I 300 1
deprivation siRNA
Food MAFbx si2
7 8 Sample I 300 1
deprivation siRNA
5
Example 7: Evaluation of in vivo efficacy of siRNA targeting proprotein
convertase
subtilisin/kexin type 9 (PCSK9) siRNA formulated in reverse micelles to
inhibit PCSK9 protein
expression
The aim of this study was to evaluate the efficacy of PCSK9 siRNA formulated
in reverse micelles
according to the procedure below (sample J) to decrease PCSK9 protein
expression when delivered by
rectal route compared to same dosage of unformulated PCSK9 siRNA delivered
intravenously in
C57B1/6J mice.
PCSK-9 siRNA is a double stranded siRNA comprising 21 nucleotides and designed
to to allow
inhibition of PCSK9 protein expression.
Sample J: 14.3 g of lecithin were dissolved in 8.6 g absolute ethanol by
magnetic stirring at 300 r/min
for 10 minutes at room temperature. 2.4 g of phytosterol were added to the
mixture and stirred in the
same conditions. 57.8 g of glycerol monooleate were added thereto and magnetic
stirring was carried
out at 500 r/min for 60 minutes at 37 C. 694.8 mg of a siRNA solution
containing 5797 1..ig of PCSK9
siRNA were added to 4819.4 mg of the oil mixture and stirred at room
temperature by magnetic
stirring between 300 and 500 r/min for 30 minutes to form reverse micelles
containing 1000 lig
PCSK9 siRNA/m1 (density of 0.95).
CA 02792137 2012-09-05
WO 2011/117334 28
PCT/EP2011/054512
Sample 15: 2.4 g of purified water was added to 16.6 g of the oil mixture
prepared according to
sample J and stirred at room temperature by magnetic stirring between 300 and
500 r/min for 30
minutes to form "empty" reverse micelles.
Administered products:
- Sample J: reverse micelles prepared according to above procedure at 1000 lag
PCSK9 siRNA/ml,
delivered at 1 ml/kg by rectal route for 10 days
- Sample 15: "empty" reverse micelles, delivered at 1 ml/kg by rectal route
for 10 days
- Unformulated PCSK9 siRNA: naked siRNA in solution at 1000 lag PCSK9
siRNA/ml, delivered at 1
ml/kg by intravenous route for 10 days
- Saline buffer delivered at 1 ml/kg by intravenous route for 10 days
C57B1/6J mice (7 or 8 mice per group) were treated as described in table
below. PCSK9 siRNA
formulated in sample J delivered at 1000 jig/kg (group 1) and "empty" reverse
micelle (sample 15),
used as control (group 2), were administered by rectal route once a day for 10
days. These products
were delivered slowly with a pipette into the lower rectum, immediately after
the anal sphincter.
Animals treated intravenously for 10 days with unformulated naked PCSK9 siRNA
(group 3) or saline
buffer (group 4) were also used as controls.
All mice were sacrificed on day 11. Livers were harvested and frozen. PCSK9
protein expression was
determined by an ELISA method (R&D Systems) in accordance with the
manufacturer instructions.
Results are shown in figure 7 wich clearly demonstrate the efficacy of
treatment with reverse micelles
formulated with PCSK9 siRNA (sample J) to reduce PCSK9 protein expression in
the liver compared
to empty reverse micelles (sample 15). Furthermore, the formulation of PCSK9
siRNA in reverse
micelles according to the invention affords a better efficacy of said siRNA to
reduce PCSK9 protein
expression in the liver compared to naked PCSK9 siRNA.
Animal Delivered dose
Groups Number (ag/kg/d) Treatment
Delivered volume (ml/kg/d)
1 8 Sample J 1000 1
2 8 Sample 15 0 1
3 7 Naked siRNA 1000 1
4 7 Saline buffer 0 1
CA 02792137 2012-09-05
WO 2011/117334 29 PCT/EP2011/054512
Example 8: Evaluation of in vivo efficacy of PrP(C) siRNA formulated in
reverse micelles to
inhibit PrP(C) protein expression
The aim of this study was to evaluate the efficacy of normal prion protein
PrP(C) siRNA formulated in
reverse micelles according to the procedure below (sample K) when delivered by
rectal route to inhibit
PrP(C) protein expression in brain of C57B1/6J mice.
PrP(C) siRNA is a double stranded siRNA comprising 21 nucleotides and designed
to allow inhibition
of PrP(C) protein expression.
Sample K : 14.1 g of lecithin were dissolved in 8.5 g absolute ethanol by
magnetic stirring at 300
r/min for 15 minutes at room temperature. 2.3 g of phytosterol were added to
the mixture and stirred in
the same conditions 57.1 g of glycerol monooleate were added thereto and
magnetic stirring was
carried out at 500 r/min for 45 minutes at 37 C. 184.0 mg of a siRNA solution
containing 932 of
PrP(C) siRNA were added to 1233.6 mg of the oil mixture and stirred at room
temperature by
magnetic stirring between 300 and 500 r/min for 60 minutes to form reverse
micelles containing 618
jig PrP(C) siRNA/m1 (density of 0.94).
Scrambled (SC) siRNA is a double stranded siRNA comprising 21 nucleotides and
designed not to
allow any modulation of PrP(C) protein expression.
Sample L: 184.2 mg of a siRNA solution containing 933 jig of SC siRNA were
added to 1233.8 mg
of the oil mixture prepared according to sample K and stirred at room
temperature by magnetic stirring
between 300 and 500 r/min for 60 minutes to form reverse micelles containing
618 us SC siRNA/m1
(density of 0.94).
Administered products:
- Sample K: reverse micelles prepared according to above procedure at 618
jig PrP(C) siRNA/ml,
delivered at 1 ml/kg by rectal route for 12 days
- Sample L: reverse micelles prepared according to above procedure at 618
jig SC siRNA/ml,
delivered at 1 ml/kg by rectal route for 12 days
C57B1/6J mice were treated as described in table below. PrP(C) and SC siRNA
formulated in reverse
micelle (samples K and L) were delivered at 618 jig/kg (groups 2 and 3, 10
mice per group). Both
products were delivered slowly with a pipette into the lower rectum,
immediately after the anal
sphincter once a day for 12 days (week ends excluded). Untreated animals were
also used as controls
(group 1, 10 mice per group).
CA 02792137 2012-09-05
WO 2011/117334 30 PCT/EP2011/054512
All mice were sacrificed on day 13. Brains were harvested and frozen. PrP(C)
protein levels were
determined by an ELISA method (SPI BIO) in accordance with the manufacturer
instructions.
Results are shown in figure 8 which clearly demonstrates the efficacy of
PrP(C) siRNA formulated in
reverse micelles (sample K) to cross the blood brain barrier and reduce brain
protein expression of
PrP(C). In contrast, reverse micelles formulated with a non specific scrambled
siRNA (sample L) have
no effect on brain expression of PrP(C).
Active Delivered
Animal Delivered dose
Groups Treatment compounds volume
Number ( g/kg/d)
(ml/kg/d)
1 10 No treatment 0
2 10 Sample L Scrambled siRNA 618 1
3 10 Sample K PrP(C) siRNA 618 1
Example 9: Formulation of reverse micelles according to the invention with
antisens
oligonucleotides
The aim of this study was to formulate chemically modified antisens
oligonucleotides (ASON) in
reverse micelles according to the invention.
DMPK2467U is a gapmer ASON comprising 20 nucleotides.
Sample M: 14.3 g of lecithin were dissolved in 8.6 g absolute ethanol by
magnetic stirring at 300
r/min for 15 minutes at room temperature. 2.4 g of phytosterol were added to
the mixture and stirred in
the same conditions 57.8 g of glycerol monooleate were added thereto and
magnetic stirring was
carried out at 500 r/min for 60 minutes at 37 C. 724.6 mg of a ASON solution
containing 5973 ng of
DMPK2467U ASON were added to 4984.0 mg of the oil mixture and stirred at room
temperature by
magnetic stirring between 300 and 500 r/min for 30 minutes to form reverse
micelles containing 994
lug DMPK2467U ASON/ml (density of 0.95).
DMPKGD65 is a gapmer ASON comprising 20 nucleotides.
Sample N: 715.6 mg of a ASON solution containing 5933 jig of DMPKGD65 ASON
were added to
4986.2 mg of the oil mixture prepared according to sample M and stirred at
room temperature by
magnetic stirring between 300 and 500 r/min for 30 minutes to form reverse
micelles containing 988
jig DMPKGD65 ASON/ml (density of 0.95).
31
REFERENCES
Altmann K. H., Fabbro D., Dean N. M., Geiger T., Monia B. P., Muller M. and
Nicklin P.
Second-generation antisense oligonucleotides: structure-activity relationships
and the design of
improved signal-transduction inhibitors. Biochem Soc Trans, 1996, 24(3)630-7.
Brinkman B. M. Splice variants as cancer biomarkers. Chn Biochem, 2004,
37(7):584-94.
Brummelkamp, T.R., Bemards, R., and Agami, R. (2002); a system for stable
expression of
short interfering RNAs in mammalian cells. Science 296, 550-553.
Chan J. H., Lim S. and Wong W. S. Antisense oligonucleotides: from design to
therapeutic application. Clin Exp Pharmacol Physiol, 2006, 33(5-6):533-40.
Chauveau F., Pestourie C. and Tavitian B. [Aptamers: selection and scope of
applications].
Pathol Biol (Paris), 2006, 54(4):251-8.
Drolet D.W. et al., Pharmacokinetics and safety of an anti-vascular
endothelial growth factor
aptamer (NX1838) following injection into the vitreous humor of rhesus
monkeys, Pharm Res,
2000, 17(12):1503-10.
Dykxhoom D.M., Novina C.D., Sharp Philip A. (2003) Killing the messenger:
short RNAs
that silence gene expression. Nat Rev Mol Cell Biol. 4, 457-467.
Egholm M., Buchardt 0., Christensen L., Behrens C., Freier S. M., Driver D.
A., Berg R. H.,
Kim S. K., Norden B. and Nielsen P. E. PNA hybridizes to complementary
oligonucleotides
obeying the Watson-Crick hydrogen-bonding rules. Nature, 1993, 365 (6446):566-
8.
Gallo M., Montserrat J. M. and Iribarren A. M. Design and applications of
modified
oligonucleotides. Braz J Med Biol Res, 2003, 36(2): 143-51.
Kang S. H., Cho M. J. and Kole R. Up-regulation of luciferase gene expression
with antisense
oligonucleotides: implications and applications in functional assay
development. Biochemistry,
1998, 37(18): 6235-9.
CA 2792137 2019-01-15
31a
Kim Y. M., Choi K. H., Jang Y. J., Yu J. and Jeong S. Specific modulation of
the
anti-DNA autoantibody-nucleic acids interaction by the high affinity RNA
aptamer. Biochem
Biophys Res Comma'', 2003, 300(2):516-23.
Kurreck J. Antisense technologies. Improvement through novel
chemicalmodifications. Eur J Biochem, 2003, 270(8):]628-44.
McCaffrey A. P., Meuse L., Pham T. T., Conklin D. S., Hannon G. J. and Kay M.
A. RNA interference in adult mice. Nature, 2002, 418(6893):38-9.
CA 2792137 2019-01-15
CA 02792137 2012-09-05
WO 2011/117334 32 PCT/EP2011/054512
Mercatante D. R., Bortner C. D., Cidlowski J. A. and Kole R. Modification of
alternative splicing of
Bc1-x pre-mRNA in prostate and breast cancer cells, analysis of apoptosis and
cell death. J Biol Chem,
2001, 276(19):16411-7.
Pendergrast P. S., Marsh H. N., Grate D., Healy J. M. and Stanton M. Nucleic
acid aptamers for target
validation and therapeutic applications. J Biomol Tech, 2005, 16(3):224-34.
Rhodes A., Deakin A., Spaull J., Coomber B., Aitken A., Life P. and Rees S.
The generation and
characterization of antagonist RNA aptamers to human oncostatin M. J Biol
Chem, 2000,
275(37):28555-61.
Rimmele M. Nucleic acid aptamers as tools and drugs: recent developments.
Chembiochem, 2003,
4(10):963-7I.
Sazani P. and Kole R. Modulation of alternative splicing by antisense
oligonucleotides. Prog Mol
Subcell Biol, 2003, 31(217-39.
Singh S. K., Kumar R. and Wengel J. Synthesis of Novel Bicyclo[2.2.1]
Ribonucleosides: 2'-Amino-
and 2'-'Thio-LNA Monomeric Nucleosides. .1 Org Chem, 1998, 63(18):6078-6079.
Srebrow A. and Kornblihtt A. R. The connection between splicing and cancer. J
Cell Sci, 2006, 119(Pt
13):2635-41.
Summerton J. and Weller D. Morpholino antisense oligomers: design,
preparation, and properties.
Antisense Nucleic Acid Drug Dev, 1997, 7(3):187-95.
Venables J. P. Unbalanced alternative splicing and its significance in cancer.
Bioessays, 2006,
28(4):378-86.
Wacheck V. and Zangemeister-Wittke U. Antisense molecules for targeted cancer
therapy. Crit Rev
Oncol Hematol, 2006, 59(1):65-73.
White R. R., Sullenger B. A. and Rusconi C. P. Developing aptamers into
therapeutics. J Clin Invest,
2000, 106(8):929-34.
